IDH1 and astrocytoma (excluding glioblastoma): To evaluate whether glioma cell lines with different IDH mutation statuses may recapitulate the results obtained in glioma patients, the expression levels of miR-1/miR-26a-1/miR-487b were assessed in the cell fraction and in the paired extracellular conditioned medium of SW1783 (astrocytoma III, IDH-wt) and BT142 (oligoastrocytoma III, the only IDH-mut glioma cell line commercially available in the ATCC collection [19]) glioma cell lines.